SPI PHARMA, INC. v. ROBEN MANUFACTURING CO. INC.

CourtDistrict Court, D. New Jersey
DecidedJune 27, 2023
Docket3:21-cv-04746
StatusUnknown

This text of SPI PHARMA, INC. v. ROBEN MANUFACTURING CO. INC. (SPI PHARMA, INC. v. ROBEN MANUFACTURING CO. INC.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
SPI PHARMA, INC. v. ROBEN MANUFACTURING CO. INC., (D.N.J. 2023).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

SPI PHARMA, INC.,

Plaintiff, Civil Action No. 21-4746 (ZNQ) (DEA)

v. OPINION

ROBEN MANUFACTURING CO. INC.,

Defendant.

QURAISHI, District Judge THIS MATTER comes before the Court upon a Motion for Summary Judgment filed by Plaintiff SPI Pharma, Inc. (“SPI” or “Plaintiff”). (“Motion”, ECF No. 29.) Plaintiff filed a Brief in Support of its Motion (“Moving Br.”, ECF No. 32) and a Statement of Material Facts (“SMF”, ECF No. 31.) Defendant Roben Manufacturing Co. Inc. (“Defendant”) filed a Brief in Opposition to Plaintiff’s Motion (“Opp’n”, ECF No. 40) along with its Counter Statement of Material Facts (“CSMF”, ECF No. 41.) Plaintiff filed a Reply to Defendant’s Opposition. (“Reply”, ECF No. 46.) The Court has carefully considered the parties’ submissions and decides the Motion without oral argument pursuant to Federal Rule of Civil Procedure 78 and Local Civil Rule 78.1. For the reasons set forth below, the Court will GRANT-IN-PART and DENY-IN-PART Plaintiff’s Motion for Summary Judgment. The Court will GRANT Plaintiff’s Motion for Summary Judgment with respect to Plaintiff’s breach of contract, liquidated damages, and attorney’s fees claims, but DENY the Motion with respect to Plaintiff’s actual damages claim. I. BACKGROUND AND PROCEDURAL HISTORY A. THE PARTIES Plaintiff is a pharmaceutical and nutritional supplement company involved in manufacturing and supplying antacid actives, excipients, taste-masking technology, and drug

delivery systems. Defendant is a manufacturing company that provides custom industrial solutions to fabricate, service, and repair evaporators, reactors, pressure vessels, storage vessels, tanks, columns, and heat exchangers as well as specialty sub-components in various alloys. B. PROCEDURAL HISTORY This action commenced on March 10, 2021 when Plaintiff filed its Complaint. (“Compl.”, ECF No. 1.) The Complaint alleges one count for breach of contract arising out of an Equipment Purchase Agreement (the “Agreement”) between the parties. (See generally, id.) The Complaint also contains a second count seeking to recover its attorneys’ fees and costs pursuant to the Agreement. (Id. ¶¶ 61‒62.) The deadline to complete fact discovery was January 31, 2022. (ECF No. 23.) Thereafter, on June 17, 2022, Plaintiff filed the instant Motion for Summary Judgment.

No Motion to Dismiss was ever filed. C. UNIDISPUTED FACTS On May 23, 2019, Plaintiff sent a request for proposal (“RFP”) to Defendant and ICC Northwest (“ICC”)—two different manufacturers—seeking proposals for the design, fabrication, and delivery of thirteen tanks and one evaporator (the “Equipment”). (SMF ¶ 1; CSMF ¶ 1.) Defendant submitted a proposal in response to the RFP, and the parties spent nearly two months negotiating the terms of an agreement. (Id. ¶ 2; Id. ¶ 2.) Plaintiff and Defendant also engaged in arms-length negotiations over a liquidated damages and early completion bonus provision. (Id. ¶ 8; Id. ¶ 8.) On or about July 15, 2019, Defendant proposed a delivery date of the Equipment by Christmas 2019. (Id. ¶ 4; Id. ¶ 4.) On or about July 20, 2019, Defendant revised its proposal to offer delivery by December 20, 2019. (Id. ¶ 5; Id. ¶ 5.) Following further negotiations, on or about July 22, 2019, Defendant agreed to Plaintiff’s required delivery date of December 10, 2019.

(Id. ¶ 6; Id. ¶ 6.) The parties agreed to award Defendant an early completion bonus of 1% of the total project cost if Defendant delivered the Equipment one business week ahead of the December 10, 2019 Completion Date. (Id. ¶ 10; Id. ¶ 10.) Defendant had the lowest Purchase Order bid at $1,316,435. (Id. ¶ 11; Id. ¶ 11.) On or about July 19, 2019, Plaintiff and Defendant entered into their Agreement. (Id. ¶ 12; Id. ¶ 12.) The intended purpose of the Agreement was to fabricate Equipment that Plaintiff would use “in connection with the manufacturing of products that [it] will sell to third parties for use as ingredients in pharmaceutical products for human and animal consumption.” (Id. ¶ 13; Id. ¶ 13.) The Agreement “supersede[d] any earlier agreements, communications, or correspondence relating to the subject matter of the agreement.” (Id. ¶ 14; Id. ¶ 14.) Pursuant to the terms of the

Agreement, Defendant was to create drawings, procure and assemble materials, manufacture, test assemble, factory test, and certify conformity to design, and deliver fourteen tanks and one evaporator. (Id. ¶ 15; Id. ¶ 15.) Pursuant to Section 6.1 of the Terms & Conditions incorporated in the Agreement (“Terms & Conditions”), Defendant was required to “proceed expeditiously to complete all of the Services and deliver the undamaged Equipment and Software to [Plaintiff’s] Site by the Date for Delivery.” (Id. ¶ 18; Id. ¶ 18.) Defendant understood and agreed that it would use “[f]irst-class materials and workmanship . . . in all aspects of all items supplied” under the Agreement. (Id. ¶ 19; Id. ¶ 19.) The parties incorporated “Attachment 6” to the Agreement which governed liquidated damages and the early completion bonus. (Id. ¶ 20; Id. ¶ 20.) Pursuant to the liquidated damages and the early completion bonus provision, the parties “recognize[d] the delays, expenses, and difficulties involved in proving the actual loss suffered by [Plaintiff] in the event of [Defendant’s] failure to deliver the Equipment by the Completion Date.” (Id. ¶ 21; Id. ¶ 21.) The liquidated damages and early completion bonus provision addressed the

fact that any delays in the delivery of the Equipment would have a cascading effect on the rest of construction at the facility because the Equipment had to be installed in a specific order and pattern depending on the manufacturing floor; supporting structures and flooring had to then be built around the tanks; Plaintiff had to conduct evaluations, testing, and validation of the equipment to meet Food & Drug Administration regulations before starting production; and test batches of product had to be run and certified prior to fulfilling customer orders. (Id. ¶ 22; Id. ¶ 22.) The parties agreed that the amounts specified under the liquidated damages provision “reasonably approximate the actual damages that would be suffered by [Plaintiff] as a result of [Defendant’s] failure to timely meet the Completion Date” and also agreed and acknowledged that the liquidated damages provision was not a penalty provision. (Id. ¶¶ 24‒25; Id. ¶¶ 24‒25.)

The parties also agreed that, if Defendant did not deliver all of the Equipment by the Completion Date, it would be liable to Plaintiff for liquidated damages based on the following schedule: • Completion Date plus one five-day business week – 1% of total project cost; • Completion Date plus a second five-day business week – $1% of total project cost; • Completion Date plus a third five-day business week – 2% of total project cost; • Completion Date plus a fourth five-day business week – 2% of total project cost. (Id. ¶ 26; Id. ¶ 26.) The parties agreed that any Damages assessed as a result of any claims, causes of action, or lawsuits in connection with the Agreement would include “reasonable legal and other professional fees and expenses.” (Id. ¶ 28; Id. ¶ 28.) On or about August 27, 2019, Defendant disclosed to Plaintiff that it was facing delays

with its heads supplier, which would delay the ultimate delivery of the Equipment. (Id. ¶ 30; Id. ¶ 30.) By early September 2019, Defendant disclosed that only three of the fourteen contracted- for tanks were expected to be delivered by the Completion Date. (Id. ¶ 31; Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Stone, Sand and Gravel Co. v. United States
234 U.S. 270 (Supreme Court, 1914)
United States v. Brooks-Callaway Co.
318 U.S. 120 (Supreme Court, 1943)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Siegel Transfer, Inc. v. Carrier Express, Inc.
54 F.3d 1125 (Third Circuit, 1995)
Ontario Hydro v. Zallea Systems, Inc.
569 F. Supp. 1261 (D. Delaware, 1983)
Phillips Home Builders, Inc. v. Travelers Insurance Co.
700 A.2d 127 (Supreme Court of Delaware, 1997)
Wilmington Housing Authority v. Pan Builders, Inc.
665 F. Supp. 351 (D. Delaware, 1987)
Gilbane Building Co. v. Nemours Foundation
666 F. Supp. 649 (D. Delaware, 1985)
CitiSteel USA, Inc. v. CONNELL LIMITED PARTNERSHIP
758 A.2d 928 (Supreme Court of Delaware, 2000)
VLIW TECHNOLOGY, LLC v. Hewlett-Packard Co.
840 A.2d 606 (Supreme Court of Delaware, 2003)
BioLife Solutions, Inc. v. Endocare, Inc.
838 A.2d 268 (Court of Chancery of Delaware, 2003)
VICI Racing, LLC v. T-Mobile USA, Inc.
763 F.3d 273 (Third Circuit, 2014)
Seiler v. Levitz Furniture Co. of the Eastern Region
367 A.2d 999 (Supreme Court of Delaware, 1976)
Charamella v. Barley Mill Road Homes, Inc.
142 A.2d 515 (Supreme Court of Delaware, 1958)
Curley v. Klem
298 F.3d 271 (Third Circuit, 2002)
Rhodes v. Marix Servicing, LLC
302 F. Supp. 3d 656 (D. New Jersey, 2018)
Williams v. Borough of West Chester
891 F.2d 458 (Third Circuit, 1989)

Cite This Page — Counsel Stack

Bluebook (online)
SPI PHARMA, INC. v. ROBEN MANUFACTURING CO. INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/spi-pharma-inc-v-roben-manufacturing-co-inc-njd-2023.